Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00486200 · ClinicalTrials.gov registry record · Phase 2
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 695
- Enrollment target
NCT00486200: Completed Phase 2 study, sponsored by Astellas Pharma.
NCT00486200 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 695 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (423% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00486200, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 695 participants
- Enrollment target
Study Summary
A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.
Interventions
- DRUG Placebo
- DRUG valacyclovir
- DRUG ASP2151
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 695 participants |
| Start Date | 2007-06-21 |
| Est. Completion | 2008-08-12 |
| Phase | Phase 2 |
What the finished NCT00486200 record still lists
NCT00486200 is an interventional study that assigns participants to a tested intervention. The registered 695 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (423% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00486200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00486200 about?
NCT00486200 is a clinical study titled "A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes". A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.
What is the current status of trial NCT00486200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 695 participants. The study started on 2007-06-21. Estimated completion is 2008-08-12.
What interventions are being tested in trial NCT00486200?
The interventions under investigation include: Placebo (DRUG), valacyclovir (DRUG), ASP2151 (DRUG).
Who is sponsoring clinical trial NCT00486200?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00486200's enrollment target sits among peer trials
695 46th of 2000 higher than 1,955 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05417594 · 695 participants · Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- NCT06801834 · 695 participants · Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI